These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 26597262)

  • 1. Measles Virus Neutralizing Antibody Response, Cell-Mediated Immunity, and Immunoglobulin G Antibody Avidity Before and After Receipt of a Third Dose of Measles, Mumps, and Rubella Vaccine in Young Adults.
    Fiebelkorn AP; Coleman LA; Belongia EA; Freeman SK; York D; Bi D; Kulkarni A; Audet S; Mercader S; McGrew M; Hickman CJ; Bellini WJ; Shivakoti R; Griffin DE; Beeler J
    J Infect Dis; 2016 Apr; 213(7):1115-23. PubMed ID: 26597262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rubella virus-specific humoral immune responses and their interrelationships before and after a third dose of measles-mumps-rubella vaccine in women of childbearing age.
    Haralambieva IH; Ovsyannikova IG; Kennedy RB; Goergen KM; Grill DE; Chen MH; Hao L; Icenogle J; Poland GA
    Vaccine; 2020 Jan; 38(5):1249-1257. PubMed ID: 31732325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rubella virus neutralizing antibody response after a third dose of measles-mumps-rubella vaccine in young adults.
    McLean HQ; Fiebelkorn AP; Ogee-Nwankwo A; Hao L; Coleman LA; Adebayo A; Icenogle JP
    Vaccine; 2018 Sep; 36(38):5732-5737. PubMed ID: 30107992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Similar Antibody Levels in 3-Year-Old Children Vaccinated Against Measles, Mumps, and Rubella at the Age of 12 Months or 18 Months.
    Kontio M; Palmu AA; Syrjänen RK; Lahdenkari M; Ruokokoski E; Davidkin I; Vaarala O; Melin M
    J Infect Dis; 2016 Jun; 213(12):2005-13. PubMed ID: 26908733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Influence of Sex, Body Mass Index, and Age on Cellular and Humoral Immune Responses Against Measles After a Third Dose of Measles-Mumps-Rubella Vaccine.
    Quach HQ; Chen J; Monroe JM; Ratishvili T; Warner ND; Grill DE; Haralambieva IH; Ovsyannikova IG; Poland GA; Kennedy RB
    J Infect Dis; 2022 Dec; 227(1):141-150. PubMed ID: 35994504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Third Dose of Measles-Mumps-Rubella Vaccine to Improve Immunity Against Mumps in Young Adults.
    Kaaijk P; Wijmenga-Monsuur AJ; van Houten MA; Veldhuijzen IK; Ten Hulscher HI; Kerkhof J; van der Klis FR; van Binnendijk RS
    J Infect Dis; 2020 Mar; 221(6):902-909. PubMed ID: 31112277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes.
    Saffar MJ; Fathpour GR; Parsaei MR; Ajami A; Khalilian AR; Shojaei J; Saffar H
    J Trop Pediatr; 2011 Oct; 57(5):347-51. PubMed ID: 21078605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term persistence of mumps antibody after receipt of 2 measles-mumps-rubella (MMR) vaccinations and antibody response after a third MMR vaccination among a university population.
    Date AA; Kyaw MH; Rue AM; Klahn J; Obrecht L; Krohn T; Rowland J; Rubin S; Safranek TJ; Bellini WJ; Dayan GH
    J Infect Dis; 2008 Jun; 197(12):1662-8. PubMed ID: 18419346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mumps antibody response in young adults after a third dose of measles-mumps-rubella vaccine.
    Fiebelkorn AP; Coleman LA; Belongia EA; Freeman SK; York D; Bi D; Zhang C; Ngo L; Rubin S
    Open Forum Infect Dis; 2014 Dec; 1(3):ofu094. PubMed ID: 25734162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Waning antibody levels and avidity: implications for MMR vaccine-induced protection.
    Kontio M; Jokinen S; Paunio M; Peltola H; Davidkin I
    J Infect Dis; 2012 Nov; 206(10):1542-8. PubMed ID: 22966129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of serum antibodies against measles, mumps and rubella after primary measles, mumps and rubella (MMR) vaccination in children.
    Rafiei Tabatabaei S; Esteghamati AR; Shiva F; Fallah F; Radmanesh R; Abdinia B; Shamshiri AR; Khairkhah M; Shekari Ebrahimabad H; Karimi A
    Arch Iran Med; 2013 Jan; 16(1):38-41. PubMed ID: 23273235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased humoral immunity to mumps in young adults immunized with MMR vaccine in childhood.
    Rasheed MAU; Hickman CJ; McGrew M; Sowers SB; Mercader S; Hopkins A; Grimes V; Yu T; Wrammert J; Mulligan MJ; Bellini WJ; Rota PA; Orenstein WA; Ahmed R; Edupuganti S
    Proc Natl Acad Sci U S A; 2019 Sep; 116(38):19071-19076. PubMed ID: 31481612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of immune status against measles, mumps, and rubella in young Kuwaitis: MMR vaccine efficacy.
    Madi N; Altawalah H; Alfouzan W; Al-Nakib W; Al-Roumi E; Jeragh A
    J Med Virol; 2020 Aug; 92(8):963-970. PubMed ID: 31919861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody Levels at 3-Years Follow-Up of a Third Dose of Measles-Mumps-Rubella Vaccine in Young Adults.
    Kaaijk P; Wijmenga-Monsuur AJ; Ten Hulscher HI; Kerkhof J; Smits G; Nicolaie MA; van Houten MA; van Binnendijk RS
    Vaccines (Basel); 2022 Jan; 10(1):. PubMed ID: 35062794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse Events Among Young Adults Following a Third Dose of Measles-Mumps-Rubella Vaccine.
    Marin M; Fiebelkorn AP; Bi D; Coleman LA; Routh J; Curns AT; McLean HQ
    Clin Infect Dis; 2021 Oct; 73(7):e1546-e1553. PubMed ID: 32766827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine.
    Haralambieva IH; Ovsyannikova IG; O'Byrne M; Pankratz VS; Jacobson RM; Poland GA
    Vaccine; 2011 Jun; 29(27):4485-91. PubMed ID: 21539880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity after outbreak response immunization activities among young healthcare workers with secondary vaccine failure during the measles epidemic in Korea, 2019.
    Seok H; Españo E; Kim J; Jeon JH; Choi WS; Kim YK; Kim JK; Park DW
    BMC Infect Dis; 2022 Jun; 22(1):530. PubMed ID: 35676650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life.
    Nair N; Gans H; Lew-Yasukawa L; Long-Wagar AC; Arvin A; Griffin DE
    J Infect Dis; 2007 Nov; 196(9):1339-45. PubMed ID: 17922398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-year antibody persistence in children vaccinated at 12-15 months with a measles-mumps-rubella virus vaccine without human serum albumin.
    Berry AA; Abu-Elyazeed R; Diaz-Perez C; Mufson MA; Harrison CJ; Leonardi M; Twiggs JD; Peltier C; Grogg S; Carbayo A; Shapiro S; Povey M; Baccarini C; Innis BL; Henry O
    Hum Vaccin Immunother; 2017 Jul; 13(7):1516-1522. PubMed ID: 28481690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and Use of an Endpoint Titration Assay To Characterize Mumps IgG Avidity following Measles, Mumps, and Rubella Vaccination and Wild-Type Mumps Infection.
    Mercader S; McGrew M; Sowers SB; Williams NJ; Bellini WJ; Hickman CJ
    mSphere; 2018 Sep; 3(5):. PubMed ID: 30209129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.